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INTRODUCTION
HUMAN prolactin was isolated in 1971 (Lewis, Singh and Seavey) and this was
soon followed by the development of a homologous radioimmunoassay for its
measurement in plasma (Friesen, Hwang, Guyda, et al 1973). Many studies have
been carried out on patients with pathological conditions where basal plasma
prolactin levels are elevated (Edwards, Forsyth and Besser, 1971; Turkington,
1972; Franks, Murray, Jequier, et al, 1975; Ramirez, O'Neill, Bloomer and Jubiz,
1977). The most important clinical application of these studies has been the
measurement of plasma prolactin in patients with secondary amenorrhoea. With
the advent of prolactin-lowering drugs such as bromocriptine and the development
of the transsphenoidal approach to hypophysectomy, it has been possible to treat
these patients successfully (Lutterbeck, Pryor, Varga and Wenner, 1971; Hardy,
1971). This paper describes the results of investigation and management of 53
patients with hyperprolactinaemia seen in the Gynaecology/Endocrine Clinic of
the Royal Victoria Hospital, Belfast.
PATIENTS AND METHODS
Basal plasma levels of prolactin, luteinizing hormone (LH), follicle stimulating
hormone (FSH), 17-,B oestradiol, progesterone and testosterone were measured in
220 patients who presented with menstrual abnormalties or infertility and with
hirsutism in a few. Thyroid function and a random plasma cortisol were also
measured. The blood samples were obtained between 10.00 and 12.00 hours and
were taken at least 30 minutes after each patient had been examined. Those who
were discovered to have elevated plasma prolactin levels were recalled and had
three consecutive blood samples taken at 30 minute intervals. The mean of these
samples was then taken at the basal plasma prolactin level. Elevated prolactin
levels were found in 42 of the 220 women. Eleven patients who were referred
with confirmed hyperprolactinaemia were similarly investigated. Forty of the
resulting 53 patients with hyperprolactinaemia also had a combined pituitary
function test performed (insulin 0.2 iu/kg bodyweight, gonadotrophin releasing
hormone (GnRH) 100 zg and thyrotrophin releasing hormone (TRH) 200 tg
intravenously). The plasma prolactin response during a 24 hour period following
2.5 mg bromocriptine orally was also measured in these 40 patients. Visual field
assessment was performed in all the patients with hyperprolactinaemia using a
Tiubinger perimeter. Lateral skull X-rays were taken in all patients and 48 had
hypocycloidal polytomography of the pituitary fossa carried out in the lateral
85projection. The X-rays were considered independently by three radiologists. They
were assessed subjectively as it has been suggested that the estimation of an
erperienced radiologist is superior to available methods of quantitative evaluation
(Steinbach, Feldman and Goldberg, 1959). The X-rays were considered to be
abnormal if there was an increase in sellar size, evidence of sellar asymmetry, a
double contour of the sellar outline, thinning of the bony contour of the sella or
localised erosion of the sellar floor. In cases where the radiologists did not agree
the X-rays were considered jointly, and if no agreement was then reached, they
were classified as equivocal. Patients with abnormal X-rays who wished to conceive
had air encephalography carried out to exclude suprasellar extension of the
pituitary lesion. Twenty-five patients had computerised axial tomography of the
pituitary fossa carried out in the transverse plane using an EMI-5005 scanner.
This examination was performed before and after intravenous injection of 50 ml
(65 per cent) meglumine diatrizoate containing 306 mg iodine per ml.
ASSAY METHODS
Plasma prolactin was measured by radioimmunossay using 125 I labelled human
prolactin (standard - Medical Research Council Standard A, preparation 71/222,
obtained from the National Institute of Biological Standards and Control; pro-
lactin for labelling supplied by the National Institute of Arthritis, Metabolism
and Digestive Diseases, National Institutes of Health, Bethesda, USA; antibody
supplied by the Tenovus Institute for Cancer Research, Cardiff (Reagent Code
7110)). This antibody displays minimal cross reactivity with human growth
hormone, luteinizing hormone (LH), follicle stimulating hormone (FSH) and
thyroid stimulating hormone (TSH). The within-assay coefficient variation was
3.9 per cent at a plasma prolactin concentration of 400 mU/l. The between-assay
coefficient variation was 7.9 per cent at this plasma concentration. The plasma
samples were assayed in duplicate and the upper limit of the normal range of
plasma prolactin in women aged 18-30 years was founnd to be 400 mU/1. Plasma
levels of LH, FSH, 17-,B oestradiol, progesterone, testosterone, human growth
hormone (HGH), TSH, thyroxine and triiodothyronine were all measured by
radioimmunoassay (Wilson, 1979). Cortisol was measured by the Mattingly
fluorometric technique (1962) and plasma glucose was measured on an auto-
analyser by the glucose oxidase technique (Technicon).
A combined pituitary function test was carried out as described by Harsoulis,
Marshall, Kuku et al (1973). The responses of LH, FSH and TSH were taken as
the mean increase in hormone levels above the basal level 20 and 60 minutes after
the beginning of the test. The responses of growth hormone and cortisol were
assessed by the peak hormone level achieved during the test and the degree of
hypoglycaemia produced by insulin was shown by the lowest plasma glucose level
recorded during the test. The plasma prolactin response to the stimulation test
was assessed by the maximum increase in plasma prolactin levels expressed as a
percentage of the basal level and the plasma prolactin response to the bromo-
criptine inhibition test was taken as the maximum decrease, expressed as a
percentage of basal level. The results of the stimulation test were compared with
86those obtained in 11 healthy female volunteers (aged 18-32 years) during the mid-
follicular phase of the menstrual cycle and were analysed using the Mann-Whitney
U test.
RESULTS
Basal plasma prolactin levels in the 53 patients with hyperprolactinaemia are
shown in Figure 1. The highest basal plasma prolactin levels occurred in 36
patients with amenorrhoea (range 1,000-31,500 mU/1) and the lowest levels in
the 10 patients with regular menstrual cycles (range 500-2,800 mU/l). However,
there was a considerable overlap between the three subgroups. One patient was
taking thioridazine. None of the others was on any medication known to influence


































FIG. 1 Basal plasma prolactin levels in 53 hyperprolactinaemic
women with amenorrhoea (A), oligomenorrhoea (0) and
regular menses (R) (upper limit of normal 400 mU/1).
Two patients had had previous neurosurgery: one had had a transfrontal
hypophysectomy for a pituitary chromophobe adenoma and the other had had a
craniopharyngioma aspirated. Both were on replacement therapy with thyroxine







Alowing discontinuation of oral contraceptives and in another seven symptoms deve-
loped following delivery. In one patient symptoms developed after she sustained a
head injury in a road traffic accident. Four patients had been treated with chlomi-
phene citrate without success but eight others had menstruated while on treatment
with this drug. Three of these patients had had successful pregnancies following
treatment with chlomiphene citrate and human chorionic gonadotrophin. One
patient had had a pregnancy following treatment with follicle stimulating
hormone, luteinizing hormone and human chorionic gonadotrophin. Polycystic
ovaries had been noted in four patients and bilateral wedge resection of ovaries
had been carried out without restoration of ovulation in all four of them.
Patients were considered to have galactorrhoea if they had a history of
abnormal lactation or if this could be demonstrated on examination. Twenty of
the 36 patients with amenorrhoea, two of the seven patients with oligomenorrhoea
and one of the 10 patients with regular menses had galactorrhoea.
Visual fields were assessed clinically in all the patients and were documented
using a Tiibinger perimeter. None of the patients had any evidence of temporal
field loss suggestive of pressure on the optic chiasma.
X-rays of the pituitary fossa were abnormal in 19 of the 48 patients who had
hypocycloidal polytomography performed. In 23 patients they were normal and
in the remaining six patients the appearances were equivocal. Basal plasma
prolactin levels were highest in the patients with abnormal fossae (range 2,100-31,
500mU/1) and the lowest in the patients with normal fossae (range 500-1,500
mU/l) but again there was considerable overlap between the subgroups. Of the 25
patients in whom CT-scans were carried out nine had normal plain X-rays and
these nine had all normal CT-scans. The three patients who had equivocal plain
X-rays all had normal CT-scans and of the 13 patients with abnormal plain X-rays,
10 had normal and only three had abnormal CT-scans.
Basal levels of TSH, thyroxine and tri-iodothyronine were similar to those in
normal females of the same age as were the basal plasma levels of LH, FSH,
progesterone and testosterone. The basal plasma levels of 17-f? oestradiol in the
hyperprolactinaemic patients with amenorrhoea were compared with those in
normoprolactinaemic patients of the same age who had amenorrhoea of pituitary
or hypothalamic origin. The mean oestradiol level in the hyperprolactinaemic
patients (190 ± 20 pmol/l) was found to be significantly lower (p<0.05) than in
the normoprolactinaemic patients (260 + 20 pmol/l). It was also found that there
was a significant correlation between basal plasma prolactin level and 17-,8
oestradiol level in these patients when the results were analysed by non-parametric
tests using Kendall's rank correlation coefficient (Tau=0.31 ; p>0.01).
The TSH, LH, FSH, growth hormone, cortisol responses to the stimulation
test are shown in Table 1. As none of the patients had adrenal disease the cortisol
response was taken to reflect ACTH release by the pituitary to this test. The
plasma prolactin response was diminished in all patients compared with control
subjects. The response to the bromocriptine inhibition test was a similar in all the
patients and showed a fall in plasma prolactin of 80 + 5 per cent.
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Results of pituitary tests in 40 hyperprolactinaemic women
HORMONE RESPONSE
EXAGGERATED NORMAL IMPAIRED
TSH 5 35 0
LH 6 30 4
FSH 24 15 1
HGH 36 4
CORTISOL 40 0
Twenty-three of the patients were treated with bromocriptine. Two had
transsphenoidal hypophysectomies and 20 remain under observation without any
treatment. The remaining eight patients returned to their referring gynaecologists
for treatment after initial investigations had been completed. Plasma prolactin
levels were restored to normal in 20 of the 23 patients treated with bromocriptine.
Two of the remaining three patients defaulted from the clinic before they had been
adequately treated. In the third patient plasma prolactin levels remained elevated
despite increasing the dose of bromocriptine to 45 mg per day. In the amenorrhoeic
patients menses were restored in 18 to 78 (mean 40) days after starting treatment.
Ovulatory menstrual cycles as shown by a biphasic temperature record and an
elevation of plasma progesterone during the second half of the cycle were
e;stablished on a dose of bromocriptine of 5 to 10 mg per day. Relief of
galactorrhoea was experienced within six weeks in all who had this symptom at the
onset of treatment.
Details of eight patients who conceived are shown in Table 2. All patients
were required to undertake barrier contraceptive measures until three menstrual
cycles had been completed. Contraceptive measures were then discontinued and
they were allowed to attempt to conceive. The absence of a predicted menstrual
period and the continued elevation of basal body temperature suggested the
possibility of pregnancy. When this was confirmed treatment with bromocriptine
was discontinued. After delivery all patients who attempted to breast feed
succeeded in doing so. Plasma prolactin levels remained elevated post partum in
all the patients but despite this one had spontaneous return of menses. All
patients with an equivocal or abnormal pituitary fossa before pregnancy were
re-Xrayed after delivery. No changes were seen in the radiological appearances
of the pituitary fossae of any of them.
Two patients were selected for treatment by transsphenoidal hypophysectomy.
Both had evidence of suprasellar extension of the pituitary on air encephalography.
Pituitary function tests carried out before and after surgery showed no impair-
89TABLE 2
Clinical details of eight hyperprolactinaemic women who conceived on
bromocriptine treatment
A - amenorrhoea 0 - oligomenorrhoea G - galactorrhoea
ment following surgery. In the first patient plasma prolactin levels fell to normal
24 hours after surgery (Figure 2) and menses resumed 28 days after a lapse of six
years. She conceived seven months after surgery and delivered a full term 3,500g
baby girl. In the second patient the plasma prolactin levels did not return to
normal after surgery and she continued to have amenorrhoea and galactorrhoea.
She was started on bromocriptine and menses were established. Three months later
she conceived but aborted after eight weeks. She was restarted on bromocriptine
and is now 20 weeks pregnant.
Twenty patients have received no treatment and eleven remain unchanged.
One patient resumed normal menses without any treatment although her plasma
prolactin levels are still elevated. Two patients with secondary amenorrhoea and
elevated plasma prolactin levels became pregnant without treatment and without
developing any menses. Both successfully completed uneventful pregnancies.
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FIG. 2 Plasma prolactin levels following transsphenoidal partial hypophysectomy in one
patient.
DISCUSSION
The incidence of hyperprolactinaemia in the patients studied here was 19 per
cent and was 28 per cent in the patients with amenorrhoea. This compares with
a reported incident of 13.4 to 39 per cent (Bohnet, Dahlen, Wuttke and Schneider,
1975; Franks Murray, Jequier et al, 1975; Glass, Williams, Butt et al, 1976; Bergh,
Nillius and Wide, 1977; Pepperell, Bright and Smith, 1977; Seppala, Lehtovirta
and Ranta, 1977; Shearman and Frazer, 1977). The variation in incidence in the
reported series is likely to be due to differences in patient groups and to reflect
the different pattern of patient referral to each centre. The incidence of galactorr-
hoea in the patients studied here was 38 per cent and is similar to that reported by
others (Bohnet et al, 1975; Franks et al, 1975; Seppala et al, 1977). It is consider-
ably lower than that reported by Glass et al (1976), Thorner and Besser (1977),
Bergh, Nillius and Wide (1977) and Pepperell, Bright and Smith (1977), all of
whom reported an incidence of galactorrhoea of approximately 80 per cent cent.
Differences are probably due to definitions of what constitutes galactorrhoea and
differences in examination technique.
91Eight patients were referred with hyperprolactinaemia after discontinuation of
oral contraceptives. It is not certain whether the use of these drugs predisposes
to the development of hyperprolactinaemia and it should be noted that some of
the patients had abnormal menses before starting on oral contraceptives. However,
it has been suggested that longterm use of oral contraceptives can result in
stimulation of otherwise silent pituitary tumours and lead to hyperprolactinaemia
(Sherman and Korenman, 1978). Polycystic ovaries were documented in four
patients studied here. This finding has been noted by others (Thorner, McNeilly,
Hagan and Besser, 1974, Sepala and Hirvonen, 1975) and it has been suggested
that it may be related to elevated androgen levels in some of these patients.
However, only two of the patients studied here had elevated testosterone levels
and only one of them had evidence of polycystic ovaries.
The finding that 17-fl oestradiol levels in hyperprolactinaemic patients with
amenorrhoea were lower than those in similar normoprolactinaemic patients and
the finding of a significant negative correlation between basal plasma prolactin
and 17-,8 oestradiol levels would support the hypothesis that there is a direct and
dose related action of prolactin on the ovary. These findings are similar to those
of Franks and Jacobs (1977) and Reyes, Gomez and Fairman (1977) but are at
variance with those of Bergh, Nillius and Wide (1977).
Tests of pituitary function performed in 40 patients showed no consistent
pattern. There was an exaggerated TSH response to TRH in five patients. This is
similar to the findings of Thorner and Besser (1977) and it has been suggested that
it is due to functional dopamine deficiency at the pituitary or hypothalamic level
(Besses, Burrow, Spaulding and Donabedian, 1975). The gonadotrophin response
to GnRH was very variable being exaggerated in some patients and impaired in a
few with very large pituitary tumours. Growth hormone response to hypoglycaemia
was also impaired in four with large pituitary tumours. The cortisol response was
normal and the prolactin response was impaired in all the patients. Although
these tests are useful for assessing pituitary function, the responses are so
variable that it is not possible to use them to distinguish patients with pituitary
tumours from patients with hyperprolactinaemia due to other causes. Muller,
Genazzani, Camanni et al (1978) described a test using nomiphensine which is the
only test that is claimed to be able to distinguish between hyperprolactinaemic
patients with and without pituitary tumours.
None of the patients studied here had visual field defects due to pressure
effects on the visual pathways. This finding is similar to that of Kase, Andriole
and Sobrinho (1973) and Jones and Kemmann (1976). It is not surprising as most
patients with hyperprolactinaemia do not have large pituitary tumours. In this
series 19 of the 48 patients who were fully investigated radiologically were
considered to have abnormal pituitary fossae but only six had gross changes
compatible with the presence of a large pituitary adenoma. The remainder had
changes compatible with the presence of a pituitary microadenoma. The
importance of carrying out polytomography in these patients was stressed by
Vezina and Sutton (1974). They found a sella of normal size in 14 out of 20
patients who subsequently were shown to have abnormalities on tomography
92compatible with the presence of a small pituitary adenoma. Transsphenoidal
surgery later confirmed the presence of a tumour in each case.
Computerised transverse axial tomography was performed in 25 patients in this
series. It was found to be of no value in confirming the presence of an intrasellar
tumour or in excluding suprasellar extension of the pituitary. Part of the difficulty
was due to the fact that the X-ray beam width in the scanner used was 13 mm but
it is hoped that narrowing this beam width and introducing special computer
procedures to obtain coronal and sagittal views of the skull will help to improve
the diagnostic value of this procedure. At present air encephalography and
metrizamide cisternography are the only reliable methods of excluding suprasellar
extension of the pituitary. This is of primary importance for selection of approp-
riate treatment for the patient with hyperprolactinaemia.
Twenty-three of the patients in this series were treated with the dopamine-
agonist bromocriptine. Those who wished to become pregnant were only treated
after suprasellar extension of the pituitary had been ruled out (see below).
Patients who did not wish to conceive but who were known to have enlargement
of the pituitary fossa were only treated after they had been fully informed of
possible complications of an unplanned pregnancy and had agreed to undertake
barrier contraception if appropriate. Treatment proved to be highly successful in
all but one patient in whom plasma prolactin levels were not restored to normal
even on 45 mg bromocriptine per day. This woman had normal growth hormone
and cortisol responses to hypogycaemia, a normal TSH response to TRH and
exaggerated LH and FSH responses to GnRH. At follow up she was reassessed
and as the radiological appearance of the pituitary fossa was then considered to
be abnormal, she was offered a transsphenoidal hypophysectomy which she
declined.
All the eight patients who wished to conceive succeeded in doing so. There are
two major concerns about treating these patients with bromocriptine. The first is
the possibility of teratogenic effects of this drug and in order to reduce this the
drug was stopped as soon as the pregnancy was confirmed. However, the patients
had all conceived at least four weeks earlier and the fetus had been exposed to
bromocriptine during that time. Despite this none of the children born to the
mothers was found to have any congenital abnormality. Griffith, Turkalj and
Braun (1978) reported the outcome of 448 completed pregnancies in mothers
treated with bromocriptine in the early weeks of pregnancy and found no increase
in the frequency of spontaneous abortion, twin pregnancy or congenital malfor-
mation compared with the general population. The second concern about the use
of bromocriptine in these patients is the possibility that an underlying pituitary
tumour may expand during pregnancy. The exact risk of this occuring is unknown
but there are a number of reports of patients in whom it has occurred and who
have been successfully treated (Kajtar and Tomkin, 1971; Child, Gordon, Mashiter
and Joplin, 1975; Gemzell, 1975; Thorner, Besser, Jones, et al 1975; Jewelewicz,
Zimmerman and Carmel, 1977; Linquette, Buvat, Gauthier et al 1977; Bergh,
Nillius and Wide, 1978).
93In order to avoid this complication it has been proposed that some destructive
procedure should be carried out to the pituitary before conception occurs.
Thorner et al (1975) advised external radiation but this does not always prevent
the development of visual field defects during pregnancy (Thorner et al, 1975;
Lambert, Seldenrath, Kwa and Birkenhager, 1976). Also, the possible benefits of
radiation need to be balanced against the unwanted side effects (Atkinson, Allen,
Hadden, et al 1979). Other alternative methods of preventing expansion of a
pituitary tumour during pregnancy include internal radiation with yttrium 90 as
proposed by Child et al (1975) and surgical removal of the tumour (Hardy, 1971).
The problem which remains is how likely is the patient with hyperprolactinaemia
to develop visual symptoms during pregnancy. Bergh, Nillius and Wide (1978)
reported 17 term pregnancies in 14 amenorrhoeic women with hyperprolactinaemia
and radiological evidence of pituitary tumour. Only two patients developed visual
symptoms during pregnancy and these resolved after delivery. Mornex, Orgiazzi,
Hugues et al (1978) reported no complications during pregnancy in eight patients
with slight or clear enlargment of the pituitary fossa. Of the three patients studied
here with equivocal or definite abnormality of the pituitary fossa who conceived
while on bromocriptine treatment, none developed visual complications during
pregnancy and none had radiological evidence of further pituitary enlargement
after pregnancy. It is our current practice to assess the pituitary fossa in hyper-
prolactinaemic patients by means of a lateral skull X-ray and hypocycloidal
polytomography in the lateral projection. If an abnormality is detected and the
patient wishes to conceive, suprasellar extension of the pituitary is excluded by
means of air encephalography in consultation with the neurosurgical unit. The
patient is then treated with bromocriptine. This treatment is stopped when she
conceives. She is reviewed at two weekly intervals in a joint ante-natal/endocrine
clinic where visual fields, visual acuity and fundal appearance are checked at each
visit. If suprasellar extension of the pituitary is confirmed, transsphenoidal partial
hypophysectomy is carried out. After conception such a patient is similarly
reviewed.
Twenty patients studied here have been followed up without treatment. One
has resumed normal menses although her prolactin levels are still elevated and
two conceived without treatment and completed successful pregnancies. This
shows that ovulation and pregnancy may occur in the presence of elevated
prolactin levels. It has been proposed that plasma prolactin levels interfere with
the action of the gonadotrophins on the ovary (Thorner and Besser, 1977) and
interfere with the release ofgonadotrophin releasing hormone by the hypothalamus
(Fuxe, Lofstrom, Hokfelt et al 1978). Clearly this does not occur in all hyper-
prolactinaemic patients. Some of these patients who have received no treatment
have radiological evidence of pituitary tumour. There have been several reports
of regression of pituitary tumour size in patients with longterm treatment with
bromocriptine (Vaidya, Aloorkar and Seth, 1977; Corenblum, 1978; Nillius, Bergh,
Lundberg et al 1978; Sobrinho, Nunes, Santos and Mauricio, 1978; McGregor,
Scanlon, Hall et al 1979). However, there is insufficient evidence so far to suggest
that all patients with hyperprolactinaemia and evidence of pituitary tumour
should be treated for a long period with bromocriptine when there is no other
indication for doing so.
94SUMMARY
Forty-two (19 per cent) of 220 patients with menstrual abnormalities or
infertility were found to have hyperprolactinaemia, including 32 (28 per cent) of
115 patients with amenorrhoea. Galactorrhoea occurred in 20 (38 per cent) of a
group of 53 hyperprolactinaemic patients and radiological evidence of a pituitary
tumour was found in 19 (39 per cent) of a group of 48 of them.
Studies of pituitary function showed that basal levels and reserves of the other
anterior pituitary hormones were usually normal or increased. Bromocriptine
lowered plasma prolactin levels in all patients. Examination of the pituitary fossa
by computerised axial tomography using an EMI-5005 was of no help in the
differential diagnosis of the underlying cause of the hyperprolactinaemia. The
most useful investigations in this respect were the lateral skull X-ray and poly-
tomography of the pituitary fossa.
Twenty patients were kept under review without treatment and two of them
conceived and completed successful pregnancies. Twenty-one patients were treated
with bromocriptine. Plasma prolactin levels were restored to normal in 20 and
eight who wished to conceive succeeded in doing so. Two patients with suprasellar
extension of the pituitary had transsphenoidal partial hypophysectomies and both
subsequently conceived. This form of treatment should be reserved for patients
with suprasellar extension of the pituitary who wish to conceive.
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SINCE 1969 several techniques have been developed which have given the opportunity for
analysis of various populations of haemopoietic cells and the factors which control their
multiplication and differentiation. These methods define cells and populations of cells in
functional rather than morphological terms. The contributors to this book give a very lucid
account of these methods, the physiological information which they have provided and, in
some chapters, a brief account of some of their clinical applications.
The book is not just another of these topical but ill-constructed collections of reviews
written in a jargon incomprehensible to all but a chosen few. A deliberate and largely suc-
cessful attempt has been made to present the subject in a form suitable for non-super-
specialists. Inevitably there is some overlap between different contributions but this seems
to maintain continuity rather than to irritate with tedious repetition.
The overall emphasis is on the physiological rather than the pathological. This is not a
criticism but it probably means that the book will not be immediately attractive to the
general clinician. For haematologists and immunologists it is a "must".
T.A.McN.
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